# Tae Min Kim
**Type:** Researchers
**Canonical URL:** https://scholariq.org/researchers/tae-min-kim/
## Facts
| Field | Value |
| --- | --- |
| Citations | 22,351 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 70 |
| i10-index | 335 |
| Last Known Institution | New Generation University College |
| OpenAlex ID | https://openalex.org/A5100719069 |
| ORCID iD | 0000-0001-6145-4426 |
| Works | 779 |
## Researcher papers
Showing 12 of 13.
- [Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study](https://scholariq.org/papers/epacadostat-plus-pembrolizumab-versus-placebo-plus-pembrolizumab-in-patients/)
- [Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial](https://scholariq.org/papers/dabrafenib-plus-trametinib-in-patients-with-previously-treated-brafv600e-mutant/)
- [Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma](https://scholariq.org/papers/polatuzumab-vedotin-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma/)
- [Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial](https://scholariq.org/papers/ceritinib-versus-chemotherapy-in-patients-with-alk-rearranged-non-small-cell/)
- [Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial](https://scholariq.org/papers/epcoritamab-a-novel-subcutaneous-cd3xcd20-bispecific-t-cell-engaging-antibody-in/)
- [Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial](https://scholariq.org/papers/dabrafenib-in-patients-with-brafv600e-positive-advanced-non-small-cell-lung/)
- [Phase II Randomized Trial Comparing Sequential First-Line Everolimus and Second-Line Sunitinib Versus First-Line Sunitinib and Second-Line Everolimus in Patients With Metastatic Renal Cell Carcinoma](https://scholariq.org/papers/phase-ii-randomized-trial-comparing-sequential-first-line-everolimus-and-second/)
- [Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study](https://scholariq.org/papers/osimertinib-in-patients-with-epidermal-growth-factor-receptor-mutation-positive/)
- [Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration](https://scholariq.org/papers/pan-cancer-immunogenomic-perspective-on-the-tumor-microenvironment-based-on-pd/)
- [Tracing Oncogene Rearrangements in the Mutational History of Lung Adenocarcinoma](https://scholariq.org/papers/tracing-oncogene-rearrangements-in-the-mutational-history-of-lung-adenocarcinoma/)
- [Mechanisms of Acquired Resistance to AZD9291](https://scholariq.org/papers/mechanisms-of-acquired-resistance-to-azd9291/)
## Researcher topics
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Glioma Diagnosis and Treatment](https://scholariq.org/topics/glioma-diagnosis-and-treatment/)
## Researcher university
- [New Generation University College](https://scholariq.org/institutions/new-generation-university-college/)
---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.